Verastem, Inc. (0LOV.L)
USD 5.58
(25.11%)
USD 5.58
(25.11%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -87.36 Million USD | -18.31% |
| 2022 | -73.84 Million USD | 8.94% |
| 2021 | -81.1 Million USD | -19.75% |
| 2020 | -67.72 Million USD | 59.97% |
| 2019 | -169.17 Million USD | -133.56% |
| 2018 | -72.43 Million USD | -6.83% |
| 2017 | -67.8 Million USD | -86.06% |
| 2016 | -36.44 Million USD | 37.03% |
| 2015 | -57.86 Million USD | -8.43% |
| 2014 | -53.36 Million USD | -29.52% |
| 2013 | -41.2 Million USD | -28.82% |
| 2012 | -31.98 Million USD | -133.75% |
| 2011 | -13.68 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -33.86 Million USD | -23.73% |
| 2024 Q2 | -8.25 Million USD | 75.62% |
| 2023 FY | -87.36 Million USD | -18.31% |
| 2023 Q3 | -20 Million USD | 17.61% |
| 2023 Q4 | -27.36 Million USD | -36.81% |
| 2023 Q2 | -24.28 Million USD | -88.91% |
| 2023 Q1 | -12.85 Million USD | 23.59% |
| 2022 Q1 | -16.96 Million USD | -2.96% |
| 2022 FY | -73.84 Million USD | 8.94% |
| 2022 Q4 | -16.82 Million USD | 7.08% |
| 2022 Q3 | -18.1 Million USD | 17.54% |
| 2022 Q2 | -21.95 Million USD | -29.37% |
| 2021 Q4 | -16.48 Million USD | 27.67% |
| 2021 Q3 | -22.78 Million USD | -34.81% |
| 2021 Q2 | -16.9 Million USD | -12.45% |
| 2021 Q1 | -15.03 Million USD | 24.33% |
| 2021 FY | -81.1 Million USD | -19.75% |
| 2020 Q3 | 13.13 Million USD | 157.1% |
| 2020 FY | -67.72 Million USD | 59.97% |
| 2020 Q1 | -37.99 Million USD | 2.02% |
| 2020 Q2 | -23.01 Million USD | 39.43% |
| 2020 Q4 | -19.86 Million USD | -251.2% |
| 2019 FY | -169.17 Million USD | -133.56% |
| 2019 Q4 | -38.77 Million USD | -28.65% |
| 2019 Q3 | -30.13 Million USD | 28.57% |
| 2019 Q2 | -42.19 Million USD | -10.74% |
| 2019 Q1 | -38.1 Million USD | -235.73% |
| 2018 Q3 | -21.66 Million USD | -17.97% |
| 2018 Q4 | -11.34 Million USD | 47.62% |
| 2018 Q2 | -18.36 Million USD | 12.75% |
| 2018 Q1 | -21.05 Million USD | -15.44% |
| 2018 FY | -72.43 Million USD | -6.83% |
| 2017 FY | -67.8 Million USD | -86.06% |
| 2017 Q1 | -13 Million USD | -11.58% |
| 2017 Q4 | -18.23 Million USD | 21.15% |
| 2017 Q3 | -23.12 Million USD | -72.12% |
| 2017 Q2 | -13.43 Million USD | -3.31% |
| 2016 Q2 | -8.56 Million USD | -3.32% |
| 2016 Q3 | -7.92 Million USD | 7.55% |
| 2016 Q1 | -8.29 Million USD | 30.09% |
| 2016 FY | -36.44 Million USD | 37.03% |
| 2016 Q4 | -11.65 Million USD | -47.12% |
| 2015 FY | -57.86 Million USD | -8.43% |
| 2015 Q4 | -11.86 Million USD | 23.19% |
| 2015 Q3 | -15.44 Million USD | -0.44% |
| 2015 Q2 | -15.37 Million USD | -1.3% |
| 2015 Q1 | -15.18 Million USD | -8.83% |
| 2014 FY | -53.36 Million USD | -29.52% |
| 2014 Q3 | -13.33 Million USD | -2.38% |
| 2014 Q2 | -13.02 Million USD | 0.31% |
| 2014 Q1 | -13.06 Million USD | -15.35% |
| 2014 Q4 | -13.94 Million USD | -4.63% |
| 2013 FY | -41.2 Million USD | -28.82% |
| 2013 Q1 | -9.03 Million USD | -14.09% |
| 2013 Q2 | -10.25 Million USD | -13.42% |
| 2013 Q3 | -10.59 Million USD | -3.33% |
| 2013 Q4 | -11.32 Million USD | -6.92% |
| 2012 Q2 | -6.82 Million USD | 0.67% |
| 2012 FY | -31.98 Million USD | -133.75% |
| 2012 Q1 | -6.87 Million USD | -14.42% |
| 2012 Q3 | -10.36 Million USD | -51.9% |
| 2012 Q4 | -7.92 Million USD | 23.59% |
| 2011 Q4 | -6 Million USD | -48.38% |
| 2011 Q3 | -4.04 Million USD | -62.86% |
| 2011 Q2 | -2.48 Million USD | -116.84% |
| 2011 Q1 | -1.14 Million USD | 0.0% |
| 2011 FY | -13.68 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | 71.678% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -61.229% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 1.259% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 107.046% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 75.186% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 80.155% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 42.364% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -83.911% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 68.36% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 63.481% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 152.114% |
| bluebird bio, Inc. | -211.91 Million USD | 58.772% |
| Blueprint Medicines Corporation | -506.98 Million USD | 82.767% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 26.281% |
| Imunon, Inc. | -19.51 Million USD | -347.692% |
| Adicet Bio, Inc. | -142.65 Million USD | 38.758% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 182.313% |
| Dynavax Technologies Corporation | -6.38 Million USD | -1267.46% |
| Editas Medicine, Inc. | -153.21 Million USD | 42.979% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 88.512% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 58.247% |
| Exelixis, Inc. | 207.76 Million USD | 142.051% |
| FibroGen, Inc. | -284.23 Million USD | 69.262% |
| Geron Corporation | -184.12 Million USD | 52.551% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 131.026% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 20.977% |
| Illumina, Inc. | -1.16 Billion USD | 92.475% |
| Incyte Corporation | 597.59 Million USD | 114.62% |
| Insmed Incorporated | -749.56 Million USD | 88.344% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 81.844% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 76.148% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 80.324% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 106.434% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -107.036% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 111.076% |
| Evolus, Inc. | -61.68 Million USD | -41.634% |
| Myriad Genetics, Inc. | -112 Million USD | 21.994% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 134.989% |
| OPKO Health, Inc. | -188.86 Million USD | 53.741% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 83.699% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 6738.83% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 98.988% |
| Waters Corporation | 642.23 Million USD | 113.604% |
| Zoetis Inc. | 2.34 Billion USD | 103.727% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 102.414% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 101.457% |
| Biogen Inc. | 1.16 Billion USD | 107.525% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 66.115% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 102.21% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -95.876% |
| Homology Medicines, Inc. | -53.74 Million USD | -62.564% |
| Nektar Therapeutics | -276.05 Million USD | 68.352% |
| TG Therapeutics, Inc. | 12.67 Million USD | 789.449% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -1.714% |
| Perrigo Company plc | -12.7 Million USD | -587.929% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -119.185% |